Program Partner: PharmaBioSource, Inc.
Audiovisual Sponsor: J-STAR Research, Inc.
Beverage Break Sponsor: Univar USA
Enhanced audiovisual system.
New for 2017, this program focuses on the specialized issues of emerging pharmaceutical and biopharmaceutical companies, an important customer base for suppliers and partnering source for larger companies. Gain perspectives from pharmaceutical companies, investors, and analysts on the key financing, investor, and partnering trends for this sector and insight on project management and the importance of CMC (chemistry, manufacturing, and controls) readiness of small companies in investor valuations and partnering potential.
Emerging Pharma Market Overview Financing trends and partnership activity with larger pharmaceutical companies are important measures of the health of emerging pharmaceutical companies. So how did this sector fared in 2016, and what can be expected for 2017? Gain the needed market insight to help guide your decision-making when partnering with smaller pharmaceutical companies by getting answers to the following questions:
Richard Harrison, Chief Scientific Officer, Clarivate Analytics (formerly the IP and Sciences Business of Thomson Reuters)
Innovation in Project Management Successful supplier relationship management is crucial in bringing a project to fruition, but how can sponsor companies and contract manufacturing organizations (CMOs) take their campaigns to the next level? In a co-presentation, learn of best practices and key success factors that one pharmaceutical company and CMO took to resolve challenges and apply innovative approaches in project management.
CMC Readiness: Does It Matter to Investors? As emerging pharmaceutical companies seek to partner with larger pharmaceutical companies and/or raise funding through public and private investors, how important is CMC (chemistry, manufacturing and controls) readiness in these investment decisions? Although the market strength of drug candidates or commercial products drive deal-making and funding, can CMC be a deal breaker?
Gain the insight of an investor into his decision-making in valuations and the experience gained from a seasoned pharmaceutical executive.
Attendees should pre-register and pre-pay for DCAT Week programs and events before March 15, 2017 (5pm ET). Confirmations and receipts will be emailed to registrants when payment is received.
Member Badges: On or about Thursday, March 16, 2017, DCAT members will receive an email with an e-ticket attachment confirming all of their pre-registrations for DCAT Week. Attendees should print the e-ticket (or store it on their phone) and bring it with them to DCAT Week. The QR code on the ticket can be used to quickly print a member badge or to scan attendees into all of the programs and events they have pre-registered for throughout the week. A separate badge system will be used for non-member registrants.
Badge Pickup Locations during DCAT Week:
Walk-ins are welcome if space permits. All walk-ins must pay with a credit card or check. Walk-ins cannot be invoiced.
Speaker bios have been requested from presenters and will be posted here as they are received.
Loren A. Busby, CFA is the Managing Member of Cresco Advisors LLC, where she works directly with fund managers and HNW investors to build value in privately held companies. She typically takes an operating role or board seat and has worked in diverse industries, including healthcare, HIT, technology, manufacturing and consumer sectors in the US, European Union, and Israel. Most recently, she served as chief financial officer of Promosome LLC, a synthetic biology company with patented mRNA-reengineering tools that increased protein expression in various platforms. Prior to founding Cresco Advisors, she was a Partner with NGN Capital LLC, a late-stage, healthcare-focused venture fund with more than $400 million in private and public investments. At NGN, Ms. Busby was integrally involved in all aspects of transaction sourcing, negotiation, analysis, exit strategies and execution, and overall fund management. She joined NGN Capital from Walden Capital Partners L.P., where she invested in several small- to mid-size companies in the manufacturing, distribution and technology sectors.
In the mid-1990s, Ms. Busby was with Princeton University Investment Company and Nassau Capital LLC, where she worked on direct investments and fund-of-funds investments on behalf of Princeton’s endowment. Prior to Nassau, she worked at Venture Economics, publisher of Venture Capital Journal. Ms. Busby earned a B.S. from Central Connecticut State University and an M.B.A. from Columbia University (McCain Scholar). She is currently a member of the Steering Committee for Mid Atlantic Bio Angels, a Mentor at SUNY Downstate Biotechnology Incubator, and a long-term contributor to the New York Society of Security Analysts and the CFA Institute. She is also a Chartered Financial Analyst (CFA).
Dr. Richard K. Harrison is the Chief Scientific Officer at Clarivate Analytics. He has over 30 years of experience in the life sciences industry. His career has focused on all aspects of pre-clinical drug discovery. During this time he has held positions of increasing responsibility at Aventis, Merck, DuPont and Wyeth Pharmaceuticals where he delivered numerous clinical candidates and worked on several marketed drugs. In addition, he served as a founding scientist in two successful venture funded computational and structure based drug design companies. Dr. Harrison has authored over 40 peer reviewed publications and book chapters in all areas of drug discovery and has presented over 50 invited lectures on these subjects. He earned his Ph.D. in Biophysical Chemistry and Enzymology and currently serves as an adjunct professor at several universities.
Stephen Munk, PhD, is the Site Head and President of Ash Stevens, a Division of Piramal Pharma Solutions. He is experienced in drug discovery, development, and manufacturing both as a scientist and as a manager. Prior to joining Ash Stevens in 1997, he worked at Allergan, Inc. initially as a medicinal chemist and subsequently, as the co-team leader of the adrenergic drug discovery team responsible for the commercialization the glaucoma treatment Alphagan (brimonidine). Under his leadership, Ash Stevens has received 12 US Food and Drug Administration approvals to manufacture innovator drug substances. These approvals include the oncology drugs Velcade (bortezomib), Busulfex (busulfan) Clolar (clofarabine), and Vidaza (5-azacitidine), Iclusig (ponatinib) and Ninlaro (ixazomib). Ash Stevens has won six National Institutes of Health research contacts under his leadership, including four competing renewals.
Dr. Munk earned his PhD. in organic synthesis at the University of California at Berkeley under the supervision of Henry Rapoport and subsequently completed an American Cancer Society Postdoctoral Fellowship with Dale Boger at Purdue University, where he conducted studies in drug design and molecular biology.
Dr. Munk’s work has been summarized in a number of publications and patents; a book chapter in Comprehensive Medicinal Chemistry II (Elsevier Ltd.), as well as presentations at scientific conferences and universities. Dr. Munk serves as an adjunct professor of chemistry at Wayne State University and on the Henry Ford Community College Biotechnology Advisory Board. He served on the Steering Committee of the Chemistry in Cancer Research Working Group of the American Association for Cancer Research (CICR-AACR; 2008-2010; 2011-2013; Chair, 2014), the Board of Directors of MichBio (2008 – 2014; Chairman 2010 - 2014). He also serves on various grant review committees for the federal government.
Benjamin Yerxa, PhD, is President and Co-founder of Envisia Therapeutics, a spinout of Liquidia Technologies. Previously, he was the CSO for both Liquidia and Envisia and joined Liquidia from Clearside Biomedical. Prior to Clearside, Dr. Yerxa was the Executive Vice President and Chief, Research & Development of Inspire Pharmaceuticals, a top-ranked publicly traded biotech company acquired by Merck & Co., Inc. During his time at Inspire, Dr. Yerxa helped the company build and commercialize a portfolio of innovative new products and was part of the senior management team through multiple rounds of financing, including the company’s initial public offering. Throughout his 25-year career in the pharmaceutical and biotechnology industry, Dr. Yerxa has been involved with the discovery and development of several investigational new drugs, Phase III clinical programs, new drug applications, and drug approvals. He is an inventor of DIQUAS, an innovative treatment for dry eye approved in Japan. His experience spans a variety of therapeutic areas, including ophthalmology, pulmonary, cardiovascular and HIV. Dr. Yerxa has more than 50 US patents to his name, led a variety of licensing deals, including technology transfers and manufacturing agreements, and has built several R&D and corporate functions from inception. Dr. Yerxa serves on the board of directors of the North Carolina Biotechnology Center and Sharefish.
Marriott East Side (Stuyvesant Room)
525 Lexington Avenue at 49th Street
New York, New York 10017
Map & Directions
To cancel your program registration and receive a refund, you must call the DCAT office by March 15, 2017 (5pm ET) at +1-800-640-3228.
Refunds with receptions may be subject to a processing fee due to hotel guarantees.
The DCAT organization regrets that no refunds can be given after March 15, 2017
Registration payments made by credit card will be refunded within two to three business days from the date of cancellation.
Registration payments made by check will be refunded within 20 days of the program date.
Education program topics for DCAT Week are selected and developed by members of DCAT's Education Committee and other volunteer task forces of the organization. Speakers are selected based on their expertise and/or experience related to these topics, their ability to impart important information and concepts, and their willingness to do so without promoting specific business interests. By advance meetings with speakers, reviewing materials and slide presentations, DCAT volunteers make every effort to ensure that each program is a relevant, value-added experience for our members.
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.